These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 32390596)

  • 1. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
    Su WL; Chuang SC; Wang YC; Chen LA; Huang JW; Chang WT; Wang SN; Lee KT; Lin CS; Kuo KK
    Cancer Biomark; 2020; 28(3):341-350. PubMed ID: 32390596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXM1 augments sorafenib resistance and promotes progression of hepatocellular carcinoma by epigenetically activating KIF23 expression.
    Zhu C; Guo H; Ma Z; Shi S; Zhao X; Zhai D; Zhou X; Jiang P; Xu Q; Cai J
    Biochem Biophys Res Commun; 2023 May; 656():1-9. PubMed ID: 36940637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
    Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
    Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma.
    Song BN; Chu IS
    Exp Mol Med; 2018 Jan; 50(1):e418. PubMed ID: 29303511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
    Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
    Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of AKT/AP1/FoxM1 signaling confers sorafenib resistance to liver cancer cells.
    Yan D; Yan X; Dai X; Chen L; Sun L; Li T; He F; Lian J; Cai W
    Oncol Rep; 2019 Aug; 42(2):785-796. PubMed ID: 31233189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
    Hashiba T; Yamashita T; Okada H; Nio K; Hayashi T; Asahina Y; Hayashi T; Terashima T; Iida N; Takatori H; Shimakami T; Kawaguchi K; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Takamura H; Ohta T; Honda M; Kaneko S
    Cell Mol Gastroenterol Hepatol; 2020; 10(2):269-285. PubMed ID: 32169577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ID1 overexpression promotes HCC progression by amplifying the AURKA/Myc signaling pathway.
    Wu M; Zhou Y; Fei C; Chen T; Yin X; Zhang L; Ren Z
    Int J Oncol; 2020 Sep; 57(3):845-857. PubMed ID: 32705157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
    Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
    World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-3677-3p promotes development and sorafenib resistance of hepatitis B-related hepatocellular carcinoma by inhibiting FOXM1 ubiquitination.
    He H; Zhou J; Cheng F; Li H; Quan Y
    Hum Cell; 2023 Sep; 36(5):1773-1789. PubMed ID: 37402927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
    Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
    Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
    Pinyol R; Montal R; Bassaganyas L; Sia D; Takayama T; Chau GY; Mazzaferro V; Roayaie S; Lee HC; Kokudo N; Zhang Z; Torrecilla S; Moeini A; Rodriguez-Carunchio L; Gane E; Verslype C; Croitoru AE; Cillo U; de la Mata M; Lupo L; Strasser S; Park JW; Camps J; Solé M; Thung SN; Villanueva A; Pena C; Meinhardt G; Bruix J; Llovet JM
    Gut; 2019 Jun; 68(6):1065-1075. PubMed ID: 30108162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma.
    Xia L; Huang W; Tian D; Zhu H; Zhang Y; Hu H; Fan D; Nie Y; Wu K
    J Hepatol; 2012 Sep; 57(3):600-12. PubMed ID: 22613004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The critical role of dysregulated Hh-FOXM1-TPX2 signaling in human hepatocellular carcinoma cell proliferation.
    Wang Y; Wang H; Yan Z; Li G; Hu G; Zhang H; Huang D; Wang Y; Zhang X; Yan Y; Lu Q; Cheng M; Luo S
    Cell Commun Signal; 2020 Jul; 18(1):116. PubMed ID: 32723329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
    Jiang H; Ning G; Wang Y; Lv W
    Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma.
    Zhang S; Guo H; Wang H; Liu X; Wang M; Liu X; Fan Y; Tan K
    Apoptosis; 2024 Jun; 29(5-6):768-784. PubMed ID: 38493408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
    BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of liver kinase B1 predicts poor prognosis in hepatocellular carcinoma.
    Tan X; Liao Z; Liang H; Chen X; Zhang B; Chu L
    Int J Oncol; 2018 Nov; 53(5):1913-1926. PubMed ID: 30226588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.